Dr. Ahmed on Axi-Cel Benefit in Patients With Primary Refractory LBCL
February 9th 2021
Sairah Ahmed, MD, discusses the efficacy of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with refractory large B-cell lymphoma (LBCL) who achieved complete remission (CR) to any prior treatment versus those who were primary refractory.